News and Announcements
Cellmid Records positive data in Midkine Antibody Study in Kidney Disease
- Published January 23, 2013 11:17AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
- Anti-midkine antibodies reduced mortality rate and preserved kidney function in a mouse model of diabetic nephropathy
- Kidney damage markedly reduced in treated animals
- Additional data bolsters preclinical antibody data package
- Large unmet medical need for patients with kidney disease
SYDNEY, Wednesday, 23 January 2013: Cellmid Limited (ASX: CDY) has completed its first in-life diabetic nephropathy study with the Company’s anti-midkine antibodies (MK-Ab) in a mouse model of the disease. Two of Cellmid’s proprietary MK-Ab’s were tested. Both antibodies reduced kidney damage significantly, as assessed by functional and histological analysis, with kidney structure largely preserved in the treated animals.
To read a full ASX announcement, please download a document below.